Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Luigi Manzione, P. Masullo, L Brancaccio, Antônio Rossi(Università Campus Bio-Medico), Giovanni Pietro Ianniello(Ospedale Sant'Anna), Alfonso Maiorino(Ospedale Monaldi), Roberta D’Aniello, M. Di Lanno, Carlo Crispino(Ospedale Monaldi), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), S. Cigolari(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), M.L. Barzelloni(Tumori Foundation), L. Maiorino, T Pedicini, Emiddio Barletta(Tumori Foundation)
Cited by 7
Related Papers
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation
|European Respiratory Journal|2005|383
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234